Search results
Showing 106 to 120 of 275 results for diarrhea
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
in children and are often non-allergy related, such as colic, reflux, diarrhoea, eczema and faltering growth. Failure to recognise food...
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)
This evidence summary has been withdrawn because the product is no longer available in the UK.
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.